Literature DB >> 9236138

Cardiac collagen remodeling in the cardiomyopathic Syrian hamster and the effect of losartan.

I M Dixon1, H Ju, N L Reid, T Scammell-La Fleur, J P Werner, G Jasmin.   

Abstract

Although increased deposition of collagen proteins has been described in cardiomyopathy, little is known of the temporal relationship between events in collagen gene transcription and the occurrence of cardiac fibrosis, the removal of collagen by matrix metalloproteinases (MMPs), or of the regulation of these events by angiotensin AT1 receptors in this disease. We sought to study steady-state collagen mRNA abundance and the deposition of specific collagen subtypes in right and left ventricular muscle of Syrian cardiomyopathic (CMP) hamsters at different stages of cardiomyopathy. Using zymography, we also investigated the gelatinolytic activities of different MMPs to gain some information about collagen removal in experimental hearts. Finally, we investigated the effect of AT1 receptor blockade (losartan) on collagen remodeling. We observed that the mRNA levels of types I and III collagens were significantly increased in all four experimental groups (35, 65, 120, and 200 day) in left ventricular tissue when compared to control (F1-beta strain) values. The mRNA levels of these collagen species in experimental right ventricular tissue samples were only elevated significantly in the 35 and 200 day experimental groups when compared to controls. Fibrillar collagen deposition was elevated in left and right ventricular CMP samples after a lag period from the occurrence of corresponding increases in mRNA abundance. Although 2-week losartan treatment of 65, 120 and 200 day experimental groups had no significant effect on left ventricular fibrillar collagen concentration or collagen mRNA abundance when compared to vehicle-infused CMP hamsters, AT1 receptor blockade was associated with complete regression of cardiac hypertrophy. Both MMP-1 (54 kDa band) and MMP-2 (58 and 62 kDa bands) activities were increased in left ventricular CMP tissues at 65, 120 and 200 days when compared to F1-beta controls. Losartan treatment was associated with significant attenuation of MMP activities in cardiomyopathic samples at 65 and 120 days. Thus, elevation of mRNA abundance of fibrillar collagen genes occurs at very early stages in this model of cardiomyopathy, and corresponding collagen proteins were subsequently deposited in the cardiac interstitium at later stages. As collagen concentration was significantly increased in later stages of cardiomyopathy studied herein (120 and 200 day groups), our data support the hypothesis that collagen synthesis exceeds the capacity of collagen removal during the progression of cardiomyopathy. Nevertheless, cardiac collagen remodeling may be facilitated by elevated MMP activity in cardiomyopathic stages in this experimental model, and we suggested that attenuation of MMP activity in the presence of losartan may be a cardioprotective mechanism of this agent.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9236138     DOI: 10.1006/jmcc.1997.0420

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  11 in total

1.  Activation of host tissue trophic factors through JAK-STAT3 signaling: a mechanism of mesenchymal stem cell-mediated cardiac repair.

Authors:  Arsalan Shabbir; David Zisa; Huey Lin; Michalis Mastri; Gregory Roloff; Gen Suzuki; Techung Lee
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-09-17       Impact factor: 4.733

2.  Extracellular matrix alterations in cardiomyopathy: The possible crucial role in the dilative form.

Authors:  V I Kapelko
Journal:  Exp Clin Cardiol       Date:  2001

3.  The cardiomyopathic hamster as model of early myocardial aging.

Authors:  M Minieri; R Fiaccavento; L Carosella; G Peruzzi; P Di Nardo
Journal:  Mol Cell Biochem       Date:  1999-08       Impact factor: 3.396

4.  Effects of losartan on the collagen degradative enzymes in hypertrophic and congestive types of cardiomyopathic hamsters.

Authors:  K Masutomo; N Makino; M S Fushiki
Journal:  Mol Cell Biochem       Date:  2001-08       Impact factor: 3.396

5.  Heart regeneration in adult MRL mice.

Authors:  J M Leferovich; K Bedelbaeva; S Samulewicz; X M Zhang; D Zwas; E B Lankford; E Heber-Katz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

Review 6.  Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.

Authors:  Y Y Li; A M Feldman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy.

Authors:  Y Y Li; Y Q Feng; T Kadokami; C F McTiernan; R Draviam; S C Watkins; A M Feldman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

8.  Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen.

Authors:  Arsalan Shabbir; David Zisa; Gen Suzuki; Techung Lee
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-04-24       Impact factor: 4.733

9.  Hydrogen sulfide alleviates myocardial fibrosis in mice with alcoholic cardiomyopathy by downregulating autophagy.

Authors:  Biao Liang; Ting Xiao; Junrong Long; Maojun Liu; Zining Li; Shengquan Liu; Jun Yang
Journal:  Int J Mol Med       Date:  2017-10-16       Impact factor: 4.101

10.  Tauroursodeoxycholic acid (TUDCA) attenuates pressure overload-induced cardiac remodeling by reducing endoplasmic reticulum stress.

Authors:  Shilpa Rani; Pradeep Kumar Sreenivasaiah; Jin Ock Kim; Mi Young Lee; Wan Seok Kang; Yong Sook Kim; Youngkeun Ahn; Woo Jin Park; Chunghee Cho; Do Han Kim
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.